Display options
Share it on

J Community Genet. 2015 Jul;6(3):241-9. doi: 10.1007/s12687-015-0236-2. Epub 2015 May 29.

Ethics, genetics and public policies in Uruguay: newborn and infant screening as a paradigm.

Journal of community genetics

Mariela Larrandaburu, Ursula Matte, Ana Noble, Zully Olivera, Maria Teresa V Sanseverino, Luis Nacul, Lavinia Schuler-Faccini

Affiliations

  1. Ministry of Public Health of Uruguay, 18 de Julio 1892, 11200, Montevideo, Uruguay, [email protected].

PMID: 26021874 PMCID: PMC4524831 DOI: 10.1007/s12687-015-0236-2

Abstract

Uruguay is a middle-income country and the smallest in South America. Its population is under 3.3 million. The demographic and epidemiological characteristics are similar to those of developed countries, with a high burden associated with congenital anomalies. Infant mortality rate (IMR) decreased from 37/1000 live births, in 1980, to 8.8/1000, in 2013. This is largely explained by medical and social policies. IMR related to congenital anomalies, however, remained unchanged for the last 30 years. Therefore, programmes for prevention of congenital disorders were developed, such as the National Newborn Screening Programme. Mandatory, universal, free infant screening was implemented two decades ago. The Ministry of Public Health created the Comprehensive Plan on Birth Defects and Rare Diseases (PIDCER), to develop a strategic public policy tool enabling comprehensive, universal, quality care during their entire lifetime. Recent national legislation created provisions for newborn and infant screening, including for congenital hypothyroidism, phenylketonuria, congenital adrenal hyperplasia, cystic fibrosis and medium-chain acyl-CoA dehydrogenase, via blood spot test, otoacoustic emissions, systematic physical examination and hip ultrasound. We discuss how this programme was implemented, the current situation of rare diseases, the institution managing disability in Uruguay and the development of new laws based on the MPH's PIDCER. It illustrates how Uruguay is developing public policies in the genomic era, based both on science and bioethics.

References

  1. Semin Fetal Neonatal Med. 2014 Jun;19(3):153-60 - PubMed
  2. Hum Biol. 1997 Apr;69(2):161-70 - PubMed
  3. N Engl J Med. 2003 Jun 5;348(23):2304-12 - PubMed
  4. J Pediatr (Rio J). 2008 Aug;84(4 Suppl):S80-90 - PubMed
  5. PLoS One. 2012;7(4):e36235 - PubMed
  6. Am J Med Genet C Semin Med Genet. 2008 Feb 15;148C(1):1-7 - PubMed
  7. J Community Genet. 2013 Jan;4(1):59-67 - PubMed
  8. J Public Health (Oxf). 2014 Jun;36(2):243-50 - PubMed
  9. Bioethics. 1999 Jul;13(3-4):288-93 - PubMed
  10. Community Genet. 2004;7(2-3):76-94 - PubMed
  11. Rev Esp Salud Publica. 2010 Mar-Apr;84(2):121-36 - PubMed
  12. Eur J Hum Genet. 2014 Nov;22(11):1248-54 - PubMed
  13. Pediatrics. 2006 Jun;117(6):1915-21 - PubMed
  14. J Inherit Metab Dis. 2007 Aug;30(4):466-81 - PubMed
  15. Rev Peru Med Exp Salud Publica. 2013 Oct-Dec;30(4):724-5 - PubMed
  16. Pediatrics. 2006 Jun;117(6):2290-303 - PubMed
  17. Genet Test. 2001 Fall;5(3):179-85 - PubMed
  18. J Inherit Metab Dis. 2010 Oct;33(Suppl 2):S315-20 - PubMed
  19. Science. 1920 Jan 9;51(1306):23-33 - PubMed

Publication Types